Ipca Laboratories Q2 FY27 Earnings Call: Zerodol Crosses Rs. 1,500 Cr, Guides 14-16% Revenue Growth (IPCALAB)

Ipca Laboratories Ltd held its Q2 FY27 earnings call on November 05, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Double-Digit Growth With Margin Expansion Despite Cost Headwinds

• Consolidated revenue grew ~14% YoY — to ~Rs.2,910 crore in Q2 FY 2026-2027 vs Rs.2,557 crore in Q2 FY 2025-2026.
• Consolidated EBITDA margin improved to ~22.97% — up from 21.68% in Q2 FY 2025-2026, achieved despite significant price increases in inputs, logistics, shipping, fuel and energy costs.
• Standalone EBITDA margin improved to 26.61% — vs 25.46% in Q2 FY 2025-2026.
• Domestic formulations grew ~14% YoY — to ~Rs.1,157 crore in Q2 FY 2026-2027 vs Rs.1,019 crore in Q2 FY 2025-2026.
• Standalone export formulations grew 32% — to ~Rs.653 crore in Q2 FY 2026-2027 vs Rs.493 crore in Q2 FY 2025-2026.

Zerodol Crosses Rs.1,500 Cr; Chronic Outpacing the Market

• Zerodol umbrella brand crossed Rs.1,500 crore in sales — per IQVIA (September 2026), becoming the 4th largest brand in the Indian Pharmaceutical Market (IPM).
• IPCA's IQVIA rank held at 16 — with market share improving to ~2.11% from 2.09% (IQVIA, September 2026); top 6 IPCA brands feature among the industry's top 300, with Zerodol SP improving to the 8th rank from 11th in Q2 FY 2025-2026.
• Chronic segment grew ~20% vs IPM growth of ~17% — (IQVIA, September 2026); acute grew ~11%, at par with the overall market, constrained by declining anti-malarials, marginal anti-bacterial growth and low cough-and-cold growth.
• Pain (Zerodol) franchise grew ~14% YoY in H1 FY 2026-2027 — revenue of Rs.1,216 crore vs Rs.1,065 crore (internal numbers, April-September); Q2 FY 2026-2027 growth accelerated to ~16% with segment revenue of Rs.628 crore vs Rs.543 crore.
• Pain franchise growth is volume-led — ~8-9% volume growth plus ~4-4.5% price growth; management affirmed the volume growth momentum is expected to sustain.
• Management expects 14-15% growth to continue over the next 3-4 years — for the rheumatoid arthritis and osteoarthritis portfolio (including Zerodol) from the current ~Rs.1,500 crore FY 2026-2027 base, through ~FY 2030-2031.

Broad-Based Generics Growth; UK Inflecting, Brazil Turns Profitable

• Q2 FY 2026-2027 generics growth was broad-based across geographies — Europe ~23%, Australia/New Zealand ~24%, US 31%, Canada 45%, and South Africa 46%.
• ROW promotional branded business up 19% — to ~Rs.172 crore in Q2 FY 2026-2027 (vs Rs.145 crore); generics ex-tender up ~36% to ~Rs.364 crore; institutional generics up ~45%; API up ~6%.
• UK business is inflecting — it posted a loss of ~2.5 million in FY 2025-2026, which management attributed to an aged portfolio (products genericized 15-20 years ago) selling below cost; in FY 2026-2027 the UK subsidiary has delivered profit, with management noting many products in short supply and prices returning.
• Brazil turned profitable in Q2 FY 2026-2027 — after incurring losses in the first two quarters of FY 2026-2027; management expects the Brazil business to move up in time to come (period unspecified).
• All subsidiaries except Pisgah are in profit — (Q2 FY 2026-2027 update); management cited good order positions on Pisgah's API side and expects things to start improving there by FY 2027-2028.
• US portfolio in dollar terms grew ~9% overall in Q2 FY 2026-2027 — IPCA's portfolio value growth ~74% with quarterly sales of ~$5.8 million; Unichem's portfolio at ~$38.5 million for the quarter.

Rs.30 Cr Freight Spike Caps Unichem at 11.3% EBITDA Margin

• Unichem delivered ~11.3% EBITDA margin in Q2 FY 2026-2027 — management attributed the softer margin to a freight cost spike, with ~Rs.30 crore of extra freight hitting EBITDA in the quarter.
• Unichem's other expenses rose Rs.47 crore (~47%) — from Rs.142 crore to Rs.189 crore in Q2 FY 2026-2027, of which ~Rs.31.2 crore was higher freight; air shipments jumped from ~5-6% to ~25% of total as shipping delays forced consignments by air.
• Unichem FY 2026-2027 margin guidance softened — on the earlier guidance of 10% top line growth and ~13% margins, management said EBITDA margin may remain in the 11-13% band if freight and energy costs stay high, and can move up if the situation normalizes.
• Q2 FY 2026-2027 gross margin of close to 58% is broadly sustainable — per management, though it may vary 1-2% either way given input cost fluctuations.

Institutional Guidance Raised; Branded Exports Maintained at 15-16%

• FY 2026-2027 institutional guidance of ~Rs.300 crore will be exceeded — management indicated full-year institutional sales may reach Rs.325-340 crore, since ~Rs.25 crore of shipments originally slated for FY 2025-2026 (delayed by non-availability of ships) landed in Q1 FY 2026-2027 and were never factored into the original guidance.
• Management guides conservatively on institutional business given its lumpy nature — despite H1 FY 2026-2027 institutional revenue already at Rs.236 crore (per the analyst), it does not expect this pace to continue, and the business may even come down in FY 2027-2028.
• Branded business grew ~22% in H1 FY 2026-2027 — West Asia declined ~3% on shipment delays while all other markets grew well; management maintained its FY 2026-2027 guidance of 15-16% growth.

Practically Debt-Free; FY27 Guidance Reiterated With Margin Trajectory

• FY 2026-2027 guidance reiterated, not revised — revenue growth of 14-16% (previously revised upward from 12-13%) and consolidated EBITDA margin of 22-23%; management explicitly stated it is not revising the guidelines.
• Management expects consolidated EBITDA margin to improve ~1-1.25% annually over the next 2-3 years — through ~FY 2029-2030, with standalone IPCA EBITDA margin improving ~1.5% annually.
• Entire outstanding foreign currency (dollar) debt repaid in FY 2025-2026 — timed around the onset of rupee depreciation; hence Q2 FY 2026-2027 interest cost declined rather than rose.
• Only ~Rs.155 crore of rupee term loans remain as of Q2 FY 2026-2027 — expected to reduce to ~Rs.70-75 crore by end of FY 2026-2027 and stay at that level; with ~Rs.700 crore cash on the books the company is "practically debt-free," and the residual loan is not being prepaid as it is contracted at a low rate versus returns earned on cash deployed in mutual funds.
• Interest cost of ~Rs.12 crore per quarter (analyst-cited Q1-Q2 FY 2026-2027 run rate) will decline in H2 FY 2026-2027 — per management confirmation.